Sildenafil Citrate

phosphodiesterase 5A ; Homo sapiens







530 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
451 12625845 Pharmacology of phosphodiesterase 5 inhibitors. 2003 Feb 1
452 12625847 Cardiovascular safety of PDE5 inhibitors. 2003 Feb 2
453 12694895 Effect of sildenafil (Viagra) on cerebral blood flow velocity: a pilot study. 2003 Apr 1 4
454 12695418 PDE5 inhibitor sildenafil citrate augments endothelium-dependent vasodilation in smokers. 2003 May 4
455 12761347 [3H]sildenafil binding to phosphodiesterase-5 is specific, kinetically heterogeneous, and stimulated by cGMP. 2003 Jun 13
456 12825143 [Sex, erectile dysfunction, and the heart: a growing problem]. 2003 Jun 2
457 12825147 [New treatment options for erectile dysfunction. Pharmacologic and nonpharmacologic options]. 2003 Jun 2
458 12841917 Sildenafil in erectile dysfunction: a critical review. 2003 2
459 12842049 Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity. 2003 Jul 1
460 12853767 Up and down-regulation of phosphodiesterase-5 as related to tachyphylaxis and priapism. 2003 Aug 3
461 12934045 Hypogonadism and erectile dysfunction: the role for testosterone therapy. 2003 Aug 2
462 12955149 Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. 2003 Sep 4 1
463 14551572 Phosphodiesterase type 5 inhibitors: a biochemical and clinical correlation survey. 2003 Oct 1
464 14562136 Effect of PDE5 inhibition combined with free oxygen radical scavenger therapy on erectile function in a diabetic animal model. 2003 Oct 1
465 14562139 Single step isolation of sildenafil from commercially available Viagra tablets. 2003 Oct 1
466 14569380 [Drug therapy of erectile dysfunction--the current status]. 2003 Oct 2
467 14609619 Overview of phosphodiesterase 5 inhibition in erectile dysfunction. 2003 Nov 6 1
468 14609621 Sildenafil in patients with cardiovascular disease. 2003 Nov 6 1
469 14618646 Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: a review. 2003 Dec 2
470 14622499 Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists. 2003 Dec 1
471 14622500 Erectile dysfunction in the cardiac patient. 2003 Dec 2
472 14652001 Diabetes impairs endothelium-dependent relaxation of human penile vascular tissues mediated by NO and EDHF. 2003 Dec 26 1
473 14687446 Sildenafil citrate does not affect cardiac contractility in human or dog heart. 2003 2
474 14693300 Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference. 2003 Nov 2
475 11815339 Sildenafil induces retinal vasodilatation in healthy subjects. 2002 Feb 4
476 11896473 Human PDE5A gene encodes three PDE5 isoforms from two alternate promoters. 2002 Feb 1
477 12002434 Efficacy of vardenafil and sildenafil in facilitating penile erection in an animal model. 2002 May-Jun 2
478 12086542 Neurologic, psychological, and aggressive disturbances with sildenafil. 2002 Jul-Aug 1
479 12145231 Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. 2002 Aug 4
480 12161769 Tolerability and safety profile of sildenafil citrate (Viagra) in Latin American patient populations. 2002 Aug 1
481 12192104 Effect of sildenafil on renin secretion in human subjects. 2002 Sep 1
482 12207947 Viagra (sildenafil citrate) and ophthalmology. 2002 Sep 3
483 12209148 Phosphodiesterase 5 inhibitors: current status and potential applications. 2002 Sep 2
484 12358156 Erectile dysfunction: oral pharmacotherapy options. 2002 Sep 1
485 12414329 Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. 2002 Sep 4
486 12435622 Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature. 2002 Oct 29 2
487 12437503 A Rho-kinase inhibitor, soluble guanylate cyclase activator and nitric oxide-releasing PDE5 inhibitor: novel approaches to erectile dysfunction. 2002 Nov 2
488 12442206 [Sildenafil for treatment of severe pulmonary hypertension and commencing right-heart failure]. 2002 Nov 2
489 12494279 Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus. 2002 Dec 2
490 12572636 Therapeutic strategies for managing erectile dysfunction: a step-care approach. 2002 Dec 2
491 12836729 PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes. 2002 2
492 15570464 Use of cGMP PDE5 inhibitors in the treatment of neuropathy: a review of the patent literature. 2002 May 1
493 11162575 Identification and regulation of human PDE5A gene promoter. 2001 Jan 26 4
494 11162576 Regulation of human PDE5A2 intronic promoter by cAMP and cGMP: identification of a critical Sp1-binding site. 2001 Jan 26 4
495 11289565 Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction. 2001 Feb 1
496 11289569 Sildenafil citrate, a selective phosphodiesterase type 5 inhibitor: urologic and cardiovascular implications. 2001 Feb 1
497 11306686 Antimitogenic actions of organic nitrates are potentiated by sildenafil and mediated via activation of protein kinase A. 2001 May 1
498 11351772 Phosphodiesterase 5 inhibition: effects on the coronary vasculature. 2001 Apr 1
499 11408180 Synthesis and phosphodiesterase 5 inhibitory activity of novel phenyl ring modified sildenafil analogues. 2001 Jun 1
500 11557915 The effect of sildenafil on nitric oxide-mediated vasodilation in healthy men. 2001 Sep 2